U.S. Reusable Urology Devices Market: $8.25B, 8.2% CAGR

Market Outlook

By 2032, the U.S. Reusable Urology Devices Market is expected to reach approximately USD 8.25 billion, expanding at a compound annual growth rate of 8.27% during the forecast period 2027–2032. The market stood at USD 5.12 billion in 2026, following historical values of approximately USD 4.15 billion in 2023, USD 4.42 billion in 2024, and USD 4.75 billion in 2025. Values in this report are expressed in USD billions.

The U.S. reusable urology devices industry represents a vital pillar of contemporary minimally invasive surgery, operating at the intersection of intricate clinical intervention, high-volume diagnostic screening, hospital capital equipment procurement, and rigorous sterile processing protocols. Foundational demand is supported by a substantial and expanding epidemiological burden of urolithiasis, benign prostatic hyperplasia, upper tract urothelial carcinoma, non-muscle-invasive bladder cancer, urethral stricture disease, and chronic neurogenic lower urinary tract dysfunction. In 2024, approximately 11.2% of adult men in the United States were actively managing symptomatic benign prostatic hyperplasia, representing an addressable clinical population requiring routine endoscopic evaluation, physiological testing, and operative tissue resection. Concurrently, the lifetime prevalence of nephrolithiasis in the United States exceeds 10% of the aggregate population, driven by systemic metabolic shifts, dietary trends, rising obesity rates, and climate-induced dehydration patterns. Urothelial and bladder carcinomas constitute an additional non-discretionary driver of device utilization, accounting for more than 83,000 newly diagnosed cases and approximately 16,800 deaths annually. Because bladder cancer necessitates lifelong, quarterly or semi-annual endoscopic surveillance, it creates a continuous clinical cycle that relies on durable diagnostic visualization infrastructure. This epidemiological volume translates directly into recurring utilization of capital-intensive reusable cystoscopes, semi-rigid and flexible ureteroscopes, large-bore nephroscopes, bipolar resectoscopes, console-based holmium and thulium fiber lithotripters, and their associated reprocessing ecosystems.

Urolithiasis represents one of the most volume-dense and durable sources of surgical device utilization across acute care and ambulatory networks. Diagnosed nephrolithiasis and ureterolithiasis generate millions of emergency department encounters and scheduled outpatient interventions each year, necessitating hundreds of thousands of therapeutic ureteroscopy and percutaneous nephrolithotomy procedures annually across U.S. healthcare facilities. This clinical cadence fuels continuous procurement of digital flexible ureteroscopes, rod-lens semi-rigid scopes, multi-use holmium and thulium laser delivery fibers, nitinol stone retrieval baskets, access sheaths, and intracorporeal lithotripsy generators. Although single-use endoscopes have secured visibility over recent procurement cycles, high-volume urology departments, academic medical institutions, and high-throughput ambulatory surgery centers continue to anchor their operational models around reusable platforms. Reusable instruments provide superior optical clarity, consistent mechanical torque response, active deflection articulation, and advantageous per-procedure cost amortization when procedural volume surpasses operational thresholds.

The diagnostic landscape generates an equally robust device ecosystem centered on surveillance, staging, and office-based interventions. Hematuria evaluations, double-J ureteral stent exchanges, urethral stricture calibrations, and intravesical chemo-immunotherapy instillations rely on flexible and rigid cystoscopes capable of withstanding dozens of patient cycles weekly. Across thousands of independent urology group practices, academic medical centers, and hospital outpatient departments, the installed fleet of reusable cystoscopy hardware represents the procedural foundation of daily urologic care. This infrastructure is undergoing a transition from legacy fiber-optic bundles to high-definition digital chip-on-the-tip complementary metal-oxide-semiconductor sensors. These sensors are integrated with narrow-band imaging, blue-light illumination, and automated endoscope reprocessing systems. High-volume providers are deploying digital platforms offering 4K visualization alongside closed-loop, automated sterilization platforms that eliminate cross-contamination risks, provide objective digital compliance logging, and optimize instrument turnover times between operative cases.

Historically, market revenue expanded steadily between 2023 and 2025 as surgical backlogs cleared, elective procedural volumes normalized, and integrated delivery networks modernized capital equipment fleets that were deferred during prior capital constraints. From 2027 through 2032, market expansion will be governed by the adoption of ultra-miniaturized chip-on-the-tip digital flexible scopes, high-frequency thulium fiber laser systems, automated cycle-tracking reprocessing hardware, and enterprise service contracts that de-risk maintenance costs. Device manufacturers that bundle durable therapeutic platforms with proprietary visualization towers, advanced low-temperature sterilization compatibility, and uptime-guaranteed maintenance agreements will capture market share relative to vendors offering unintegrated hardware.

Introduction

The urology sector is one of the most technologically advanced and procedurally dense disciplines within the American medical device landscape. Urological patient pathways require an extensive continuum of specialized capital hardware and reusable instrumentation. A typical clinical pathway may begin with an office-based flexible cystoscopic evaluation for microscopic hematuria under topical anesthesia, progress to an ambulatory surgery center for a rigid ureteroscopy with laser lithotripsy, and culminate in a tertiary hospital setting for a complex percutaneous nephrolithotomy or bipolar transurethral enucleation of the prostate. This clinical diversity sustains a capital ecosystem spanning visualization towers, endourological scopes, intracorporeal lithotripsy consoles, electrosurgical resectoscopes, and hospital sterile processing infrastructure.

Endourology devices constitute the largest product classification, accounting for 58.4% of total U.S. reusable urology device revenue in 2025. This segment includes flexible and rigid cystoscopes, digital flexible ureteroscopes, semi-rigid ureteroscopes, operative nephroscopes, and transurethral resectoscopes. The underlying business model is characterized by capital placement linked to long-term operational utilization. An initial investment in high-definition camera control units, xenon or LED light sources, and surgical video monitors establishes an installed base that drives continuous procurement of compatible proprietary endoscopes, reusable grasping forceps, laser delivery fibers, and maintenance service agreements over a 5- to 7-year asset lifecycle.

Hospitals and integrated delivery networks represent the primary purchasing category, accounting for approximately 62% of aggregate market demand under broad classification models. These institutions manage high-acuity surgical procedures, complex oncologic resections, staghorn calculi, and urologic trauma cases that require a broad range of durable, specialized instruments that are cost-prohibitive in single-use formats. Concurrently, ambulatory surgery centers are expanding at an accelerated rate. Driven by commercial payer site-of-service payment differentials and Medicare procedural shifts, ambulatory surgery centers are acquiring reusable platforms to optimize per-case margins across predictable, high-volume interventions such as diagnostic cystoscopy, uncomplicated ureteroscopic stone fragmentation, and outpatient prostate resections.

The procurement economics of reusable urology devices differ fundamentally from disposable or implantable device categories. Value analysis committees, hospital supply chain executives, and clinical chairs evaluate acquisitions through total cost of ownership models. These analyses encompass initial capital outlay, service contract premiums, repair intervals, per-cycle sterile processing labor, and chemical consumable costs. For high-volume urology practices, the financial viability of procedural service lines depends on amortizing capital costs across large patient cohorts. While single-use alternatives eliminate decontamination requirements, they introduce a linear, recurring cost structure that can erode operating margins in facilities conducting thousands of procedures annually. Consequently, enterprise contracts frequently involve fleet-level standardization across regional networks, pairing high-definition digital scopes with dedicated automated endoscope reprocessors to maximize clinical uptime and ensure regulatory compliance.

Regulatory oversight and infection control mandates heavily influence the design and clinical management of reusable urology hardware. The regulatory scrutiny directed at flexible endoscopes by the Food and Drug Administration, the Centers for Disease Control and Prevention, and the American Urological Association has accelerated the transition from manual decontamination protocols to validated, closed-circuit automated endoscope reprocessing and low-temperature gas plasma sterilization. Manufacturers must engineer instruments that feature smooth luminal surfaces, eliminate inaccessible internal elevator mechanisms, and incorporate aerospace-grade polymers and specialized optical adhesives capable of withstanding hundreds of harsh chemical or thermal decontamination cycles without optical degradation. Over the forecast period, competitive differentiation will depend on optical resolution, structural durability, compatibility with standardized hospital reprocessing workflows, and integrated fleet management solutions.

Key Market Drivers: What’s Fueling the U.S. Reusable Urology Devices Market Boom?

The expansion of the U.S. reusable urology devices market is underpinned by five core structural drivers spanning epidemiology, procedural economics, capital cycles, materials science, and environmental sustainability mandates.

The primary growth catalyst is the rising incidence and recurrence of urolithiasis across the United States. Alterations in population dietary patterns, characterized by elevated sodium and animal protein intake, coupled with climbing rates of obesity, type 2 diabetes, and hypertension, have increased stone disease prevalence. Warmer climatic patterns in the southern and southeastern United States have further accelerated stone formation, expanding the geographical reach of the historical “Stone Belt.” Urolithiasis is characterized by high recurrence rates, with approximately 50% of stone formers experiencing a secondary stone event within ten years. This dynamic creates an ongoing patient cohort requiring interventional ureteroscopy, percutaneous nephrolithotomy, or shock wave lithotripsy. High procedural volumes favor reusable platforms, where the initial capital investment is amortized over hundreds of surgical cases, resulting in a low per-case cost compared to single-use alternatives.

A second driver is the demographic aging of the U.S. population and the resulting burden of benign prostatic hyperplasia and urologic malignancies. The U.S. Census Bureau projects the population aged 65 and older to expand significantly through 2032. BPH affects more than 50% of men in their sixties and up to 90% of men over eighty, generating ongoing surgical volume for transurethral resection, laser vaporization, and laser enucleation. Concurrently, bladder cancer represents the sixth most prevalent malignancy in the United States, characterized by high recurrence rates that require ongoing cystoscopic surveillance. The clinical necessity of performing lifelong quarterly or semi-annual examinations creates consistent procedural volume, reinforcing health system reliance on fleets of durable, high-definition digital cystoscopes.

A third driver is the migration of urologic surgical volume toward ambulatory surgery centers. Driven by favorable commercial payer contracting, patient convenience, and specialized perioperative workflows, ambulatory surgery centers are capturing a growing share of stone management, diagnostic scoping, and outflow obstruction procedures. In the ambulatory surgery center operating model, procedural throughput and supply-chain cost management govern facility profitability. While single-use endoscopes avoid upfront capital acquisition, the cumulative operational expense of purchasing individual units for daily surgical schedules can strain center margins. Ambulatory surgery centers address this by investing in durable digital scopes paired with rapid-cycle automated endoscope reprocessors. The reusable endoscope sector generated USD 2.42 billion in 2023 and is projected to reach USD 3.95 billion by 2030, supported by ambulatory surgery center capital investment.

A fourth driver is the transition from legacy fiber-optic visualization systems to high-definition digital chip-on-the-tip architectures. Many U.S. healthcare institutions are retiring optical systems that utilize analog fiber bundles prone to pixel fracturing, light attenuation, and field distortion. Modern digital endoscopes integrate sub-millimeter complementary metal-oxide-semiconductor sensors and light-emitting diode arrays at the distal tip, delivering native high-definition and 4K video feeds directly to surgical monitors. These advanced optical architectures incorporate multi-spectral lighting, narrow-band imaging, and digital contrast enhancement, improving the visualization of flat carcinoma in situ lesions, mucosal micro-vasculature, and renal collecting system anatomy. The visualization and capital hardware segment reached USD 1.18 billion in 2023 and is on track to achieve USD 1.85 billion by 2030 as hospital systems execute planned fleet-wide digital conversions.

A fifth driver is the elevation of corporate sustainability and carbon-reduction mandates across U.S. integrated delivery networks. Leading health systems are analyzing the environmental footprint of their clinical operations, evaluating biomedical waste generation, single-use plastics volume, and supply chain carbon emissions. A single high-volume urology center utilizing disposable endoscopes generates thousands of pounds of non-recyclable, bio-hazardous polymer and battery waste annually. Reusable endoscopes and stainless-steel surgical instruments, when maintained through efficient reprocessing protocols, offer lower lifecycle environmental impacts and reduce operational disposal expenses. This environmental calculation, aligned with hospital ESG commitments, reinforces institutional demand for reusable surgical instrumentation platforms.

Innovation in Focus: How Manufacturers Are Raising the Bar?

Technological innovation across the reusable urology hardware market is focused on optical fidelity, mechanical durability, energy delivery integration, automated reprocessing validation, and intraoperative digital connectivity.

Miniaturized digital imaging sensors represent a major technological advance in flexible endourology. Early-generation flexible ureteroscopes and cystoscopes relied on thousands of coherent glass optical fibers packed into narrow instrument shafts. These fiber-optic bundles were susceptible to mechanical fracturing from excessive deflection or laser strike, leading to progressive image degradation. Modern flexible platforms incorporate sub-millimeter complementary metal-oxide-semiconductor image sensors directly at the distal tip, eliminating the optical fiber bundle entirely. This architecture delivers native 1080p and 4K digital video feeds with uniform illumination and zero pixel dropout. Furthermore, distal digital integration enables electronic chromoendoscopy, such as narrow-band imaging and blue-light fluorescence. By isolating specific absorption wavelengths of hemoglobin, these platforms illuminate the micro-vascular networks feeding urothelial neoplasms, improving diagnostic yields for non-muscle-invasive bladder cancer and upper tract urothelial carcinoma without requiring separate, dedicated optical systems.

Durability engineering represents a vital focal point for research and development budgets. Reusable flexible ureteroscopes operate under demanding mechanical conditions, requiring active primary deflection up to 275 degrees in both directions to access the lower renal pole while accommodating working instruments and laser fibers. Manufacturers are addressing mechanical failure points through advanced metallurgical and polymer engineering. Modern scope shafts utilize multi-layered, braided nitinol inner cores that optimize column strength, resist rotational kinking, and provide 1:1 torque transmission from the surgeon’s hand to the distal tip. Distal ceramic caps and laser-resistant sapphire lenses protect internal electronics from stray acoustic shock waves and thermal energy during holmium and thulium fiber laser activation. These structural enhancements have extended the mean-time-between-repairs for premium flexible scopes, improving the economic equation for healthcare facilities by reducing maintenance frequency.

The integration of intracorporeal energy delivery consoles with digital visualization platforms is transforming surgical workflow. The introduction of high-frequency thulium fiber laser systems has altered the stone management landscape. Operating at a wavelength of 1,940 nanometers, which closely matches the water absorption peak in human tissue and calculi, thulium fiber lasers achieve stone vaporization and dusting with minimal retropulsion. Reusable laser systems feature integrated console architectures that communicate directly with the endoscope visualization tower. Surgical displays present real-time laser output power, frequency, pulse duration, total delivered energy, and fluid irrigation metrics as a digital overlay on the operative field. This parameter tracking enables the surgeon to modulate energy settings without disengaging from the endoscopic view, lowering operative times and reducing thermal risks to surrounding urothelial tissue. The reusable laser and lithotripsy console market generated USD 0.85 billion in 2023 and is projected to reach USD 1.45 billion by 2030, driven by the replacement of legacy holmium systems with modular thulium fiber laser consoles.

Reprocessing infrastructure has similarly evolved through integration and automation. In response to regulatory mandates for enhanced endoscope decontamination, the auxiliary reprocessing equipment market generated USD 0.38 billion in 2023 and is projected to approach USD 0.65 billion by 2030. Innovations include multi-chamber, pass-through automated endoscope reprocessors equipped with radio-frequency identification sensors. These systems read embedded RFID tags within modern endoscope handles, automatically logging the serial number, procedure count, operator identity, cleaning chemical lot number, and cycle efficacy parameters directly to the hospital’s sterile processing software. Integrated electronic leak testing occurs dynamically throughout the decontamination cycle, identifying micro-perforations in the scope sheath before high-pressure fluid invasion can damage internal digital electronics. This systematic tracking eliminates manual documentation errors, verifies regulatory compliance, and extends the operational lifespan of reusable endoscopes.

Artificial intelligence is being integrated into surgical video processors to provide real-time diagnostic support. Machine learning algorithms, trained on vast datasets of validated urothelial pathology, analyze live video feeds during cystoscopy and ureteroscopy. These algorithms highlight mucosal margins, differentiate suspicious flat carcinomas from benign inflammatory erythema, and quantify stone volume and fragment geometry during lithotripsy. By optimizing tissue visualization and measuring stone dust granularity, integrated software enhances surgical precision while lowering procedural times.

Segmentation Insights

The U.S. Reusable Urology Devices Market is segmented on the basis of product category, disease indication, end user, technology type, and reprocessing modality.

By Product Category

Endoscopes
The Endoscopes category forms the core product classification of the market, generating USD 2.99 billion in 2026 and projected to reach USD 4.86 billion by 2032, reflecting a compound annual growth rate of 8.43% from 2027 to 2032. This category encompassed USD 2.42 billion in 2023, USD 2.58 billion in 2024, and USD 2.77 billion in 2025. Endoscopes represent the primary visualization medium across urological surgery, serving as the interface through which diagnostic surveillance and therapeutic interventions occur. The segment includes four distinct product sub-segments: cystoscopes, ureteroscopes, resectoscopes, and nephroscopes.

Cystoscopes represent the largest volume sub-segment, generating USD 1.42 billion in 2026 and expected to achieve USD 2.24 billion by 2032, expanding at a CAGR of 7.85%. Historical revenues stood at USD 1.16 billion in 2023, USD 1.24 billion in 2024, and USD 1.33 billion in 2025. Reusable cystoscopes are the most frequently deployed instruments in urology, utilized for outpatient hematuria workups, bladder cancer restaging, double-J stent placements, and foreign body retrievals. Demand is heavily concentrated in digital flexible cystoscopes featuring wide-angle deflection and ergonomic, lightweight control handles designed to minimize physician fatigue during high-volume clinic days. The integration of high-definition CMOS chips at the distal tip has accelerated the replacement of older fiber-optic instruments, providing superior mucosal visualization that aids in the identification of flat urothelial lesions.

Ureteroscopes constitute the second-largest and fastest-expanding endoscope sub-segment, generating USD 0.98 billion in 2026 and projected to expand to USD 1.68 billion by 2032 at a CAGR of 9.38%. Historical figures reached USD 0.77 billion in 2023, USD 0.83 billion in 2024, and USD 0.90 billion in 2025. This sub-segment includes both semi-rigid ureteroscopes utilized primarily for distal and mid-ureteral stone fragmentation, and digital flexible ureteroscopes designed to navigate the tortuous upper urinary tract and renal pelvis. Flexible digital ureteroscopes command premium capital price points due to their complex internal mechanics, active secondary deflection mechanisms, and specialized miniature image sensors. While single-use alternatives compete in this category, high-volume stone centers rely on durable reusable flexible ureteroscopes due to their superior torque transmission, consistent deflection angles, and favorable economic amortization across busy surgical schedules.

Resectoscopes generated USD 0.38 billion in 2026 and are projected to reach USD 0.59 billion by 2032, demonstrating a CAGR of 7.64%. The historical baseline stood at USD 0.32 billion in 2023, USD 0.34 billion in 2024, and USD 0.36 billion in 2025. Resectoscopes serve as the clinical standard for transurethral resection of the prostate for BPH and transurethral resection of bladder tumors. Technological progress within this sub-segment centers on the transition from monopolar electrosurgical systems to advanced bipolar continuous-flow resectoscopes. Bipolar configurations utilize isotonic saline as an irrigant rather than glycine or sorbitol, eliminating the risk of transurethral resection syndrome and allowing for longer, safer operative resections in patients with larger prostate volumes.

Nephroscopes generated USD 0.21 billion in 2026 and are forecasted to achieve USD 0.35 billion by 2032, representing a CAGR of 9.15%. Historical values were USD 0.17 billion in 2023, USD 0.18 billion in 2024, and USD 0.19 billion in 2025. Nephroscopes are specialized, large-lumen rigid and flexible endoscopes designed for percutaneous access to the renal collecting system during percutaneous nephrolithotomy procedures. Demand is driven by the management of complex, staghorn, or branched renal calculi exceeding two centimeters in diameter. Recent developments feature miniaturized nephroscopes designed for mini-PCNL and micro-PCNL procedures, which reduce parenchymal renal trauma, minimize blood loss, and allow for tubeless percutaneous stone clearance while maintaining continuous low-pressure irrigation.

Laser and Lithotripsy Systems
The Laser and Lithotripsy Systems category accounted for USD 1.02 billion in 2026 and is projected to expand to USD 1.68 billion by 2032, recording a compound annual growth rate of 8.68% during the forecast period. The market expanded from USD 0.82 billion in 2023 to USD 0.88 billion in 2024 and USD 0.94 billion in 2025. This category encompasses the capital consoles and energy delivery hardware utilized to fragment urinary calculi and ablate obstructing prostatic tissue. It comprises three primary sub-segments: holmium lasers, thulium fiber lasers, and extracorporeal shock wave lithotripters alongside intracorporeal pneumatic or ultrasonic devices.

Holmium lasers generated USD 0.46 billion in 2026 and are projected to reach USD 0.69 billion by 2032, advancing at a CAGR of 7.12%. Historical revenues reached USD 0.39 billion in 2023, USD 0.41 billion in 2024, and USD 0.44 billion in 2025. High-power holmium:YAG laser consoles remain widely deployed across hospital operating suites. Operating at a wavelength of 2,100 nanometers, these versatile platforms support both stone fragmentation via photothermal lithotripsy and soft tissue resection during holmium laser enucleation of the prostate. While high-power holmium consoles face competition from newer solid-state laser formats, their established clinical safety profile and capability to fragment all stone compositions sustain steady capital replacement demand.

Thulium Fiber Lasers represent the fastest-growing energy sub-segment, accounting for USD 0.34 billion in 2026 and projected to expand to USD 0.66 billion by 2032, exhibiting an 11.82% CAGR. Historical values stood at USD 0.24 billion in 2023, USD 0.27 billion in 2024, and USD 0.30 billion in 2025. Thulium fiber lasers operate at an emission wavelength of 1,940 nanometers, aligning closely with the water absorption peak in biological tissue. This physical characteristic facilitates precise stone dusting into microscopic particulates, reducing retropulsion and lowering operative times. Furthermore, thulium platforms utilize thinner laser fibers, preserving endoscope deflection mechanics and fluid irrigation rates while reducing thermal wear on reusable endoscope channels.

Extracorporeal Shock Wave Lithotripters and Intracorporeal Systems generated USD 0.22 billion in 2026 and are anticipated to attain USD 0.33 billion by 2032, tracking a CAGR of 7.14%. Historical values were USD 0.19 billion in 2023, USD 0.20 billion in 2024, and USD 0.21 billion in 2025. This sub-segment incorporates mobile and stationary shock wave lithotripsy suites alongside combination ultrasonic and ballistic intracorporeal generators deployed through nephroscopes. While flexible ureteroscopy has captured some clinical share, shock wave platforms maintain a role in the non-invasive outpatient management of solitary upper pole renal calculi, while multi-modal intracorporeal systems are utilized for the rapid debulking of large staghorn stones during percutaneous procedures.

Reusable Handheld Surgical Instruments and Accessories
The Reusable Handheld Surgical Instruments and Accessories category generated USD 0.65 billion in 2026 and is projected to expand to USD 1.02 billion by 2032, registering a CAGR of 7.79%. Historical performance showed USD 0.53 billion in 2023, USD 0.57 billion in 2024, and USD 0.61 billion in 2025. This segment incorporates mechanical instruments required to manipulate tissue, extract calculi, and access the urinary tract. It is divided into three functional sub-segments: biopsy forceps and graspers, stone extraction baskets and retrieval devices, and dilators, access sheaths, and cannulas.

Biopsy forceps and graspers accounted for USD 0.26 billion in 2026 and are projected to reach USD 0.40 billion by 2032, growing at a CAGR of 7.42%. Historical values reached USD 0.22 billion in 2023, USD 0.23 billion in 2024, and USD 0.25 billion in 2025. These instruments feature stainless steel, titanium, and tungsten construction, engineered to provide high mechanical closing force and precise tactile feedback. Reusable grasping forceps and cold-cup biopsy jaws are deployed through cystoscope channels to obtain tissue samples from suspected bladder malignancies and retrieve migrated ureteral stents.

Stone extraction baskets and retrieval devices generated USD 0.23 billion in 2026 and are projected to achieve USD 0.37 billion by 2032, representing a CAGR of 8.35%. Historical figures stood at USD 0.18 billion in 2023, USD 0.20 billion in 2024, and USD 0.21 billion in 2025. These devices utilize multi-wire, tipless nitinol geometries designed to entrap and extract calculi from the renal calyces without causing mucosal laceration. Reusable nitinol baskets maintain their shape memory across hundreds of operative deployments, resisting kink formation and allowing for the release of trapped stones when fragmentation is required prior to extraction.

Dilators, access sheaths, and cannulas generated USD 0.16 billion in 2026 and are forecasted to reach USD 0.25 billion by 2032, progressing at a CAGR of 7.60%. The historical baseline stood at USD 0.13 billion in 2023, USD 0.14 billion in 2024, and USD 0.15 billion in 2025. This sub-segment includes metallic mechanical urethral sounds, sequential fascial dilators for percutaneous renal access, reusable metal access sheaths, and high-flow continuous irrigation cannulas. These instruments are machined from surgical-grade alloys, allowing for repeated steam autoclaving without dimensional distortion or corrosion.

Reprocessing and Sterilization Systems
The Reprocessing and Sterilization Systems category was valued at USD 0.46 billion in 2026 and is projected to reach USD 0.69 billion by 2032, at a compound annual growth rate of 6.99%. Historical totals were USD 0.38 billion in 2023, USD 0.41 billion in 2024, and USD 0.43 billion in 2025. This category encompasses the capital equipment and specialized containment infrastructure required to clean, disinfect, and terminally sterilize reusable urological devices. It consists of three sub-segments: automated endoscope reprocessors, low-temperature sterilization systems, and cleaning, drying, and storage cabinets.

Automated Endoscope Reprocessors accounted for USD 0.26 billion in 2026 and are projected to reach USD 0.40 billion by 2032, expanding at a CAGR of 7.28%. Historical revenue reached USD 0.21 billion in 2023, USD 0.23 billion in 2024, and USD 0.24 billion in 2025. Automated endoscope reprocessors provide automated, validated high-level chemical disinfection for flexible cystoscopes and ureteroscopes. Modern automated reprocessors incorporate independent channel-monitoring systems that measure fluid flow, pressure, and temperature across individual lumina, identifying blockages or micro-leaks and logging processing parameters to maintain compliance with regulatory guidelines.

Low-temperature sterilization systems generated USD 0.13 billion in 2026 and are expected to achieve USD 0.20 billion by 2032, growing at a CAGR of 7.15%. Historical revenue was USD 0.11 billion in 2023, USD 0.12 billion in 2024, and USD 0.12 billion in 2025. These systems utilize vaporized hydrogen peroxide and gas plasma to achieve terminal sterilization without exposing heat-sensitive digital optics and polymer shafts to the damaging thermal stresses of conventional autoclaves. Health systems deploy low-temperature sterilization platforms to elevate infection control standards from high-level disinfection to complete sterilization across flexible endoscope fleets.

Cleaning, drying, and storage cabinets accounted for USD 0.07 billion in 2026 and are projected to reach USD 0.09 billion by 2032, at a CAGR of 5.61%. Historical figures stood at USD 0.06 billion in 2023, USD 0.06 billion in 2024, and USD 0.07 billion in 2025. Proper post-processing storage represents a recognized priority in preventing microbial recontamination and biofilm development. Positive-pressure storage cabinets circulate HEPA-filtered air through individual endoscope working channels, preventing moisture accumulation and maintaining scope sterility prior to subsequent clinical deployment.

By Disease Indication

Urolithiasis
Urolithiasis represents the largest clinical indication, generating USD 1.98 billion in 2026 and projected to expand to USD 3.29 billion by 2032, achieving a CAGR of 8.84%. Historical revenues stood at USD 1.58 billion in 2023, USD 1.70 billion in 2024, and USD 1.83 billion in 2025. Kidney stone disease generates predictable surgical procedural volume across the United States, driven by changes in nutritional habits, systemic metabolic disorders, and warming climate patterns. The therapeutic management of renal and ureteral calculi requires an integrated array of reusable hardware, ranging from semi-rigid ureteroscopes for distal impactions to digital flexible ureteroscopes, thulium fiber lasers, and percutaneous nephroscopes for complex upper-tract staghorn stones. Reusable platforms provide high mechanical control, fluid dynamics, and optical resolution, enabling urologists to clear stone burdens while controlling per-procedure device costs.

Benign Prostatic Hyperplasia
Benign Prostatic Hyperplasia generated USD 1.43 billion in 2026 and is forecasted to achieve USD 2.29 billion by 2032, advancing at an 8.16% CAGR. The historical market expanded from USD 1.15 billion in 2023 to USD 1.23 billion in 2024 and USD 1.33 billion in 2025. BPH affects aging male populations, resulting in lower urinary tract symptoms, urinary retention, and bladder outlet obstruction. The surgical management of BPH is anchored in transurethral resectoscopes and capital energy systems. While office-based therapies and minimally invasive implants continue to evolve, transurethral resection of the prostate, holmium laser enucleation, and thulium fiber laser enucleation remain reference standards for durable tissue debulking in enlarged glands. These procedures rely on durable bipolar resectoscopes, continuous-flow sheath assemblies, and high-wattage laser consoles capable of supporting hours of continuous soft-tissue vaporization and coagulation.

Urothelial Carcinoma and Bladder Cancer
Urothelial Carcinoma and Bladder Cancer accounted for USD 1.06 billion in 2026 and is projected to expand to USD 1.72 billion by 2032, registering a CAGR of 8.37%. Historical values were USD 0.85 billion in 2023, USD 0.92 billion in 2024, and USD 0.99 billion in 2025. Bladder cancer requires prolonged, recurrent clinical device utilization due to its propensity for local recurrence and progression. Surviving patients undergo surveillance cystoscopy every three to six months for multiple years following initial transurethral resection. This high surveillance frequency generates steady, non-discretionary utilization of reusable flexible cystoscopes. Technological development is focused on optical detection technologies, such as narrow-band imaging, high-definition digital sensor arrays, and fluorescence cystoscopy. These platforms improve the identification of flat carcinomas in situ and papillary lesions, allowing for targeted resections that reduce recurrence rates.

Urethral Stricture and Urologic Reconstruction
Urethral Stricture and Urologic Reconstruction was valued at USD 0.41 billion in 2026 and is projected to attain USD 0.61 billion by 2032, expanding at a CAGR of 6.88%. Historical values reached USD 0.34 billion in 2023, USD 0.36 billion in 2024, and USD 0.38 billion in 2025. Urethral stricture disease, secondary to trauma, iatrogenic instrumentation, infectious urethritis, or lichen sclerosus, requires operative dilation, optical internal urethrotomy, or open urethroplasty. This segment relies heavily on reusable rigid optical urethrotomes, specialized cold-knife blades, metallic sounds, and filiform-and-follower dilation systems. Because reconstructive procedures require structural rigidity and high mechanical torque transmission, surgeons rely on machined stainless-steel and titanium reusable instrumentation that provides tactile feedback during stricture incision and luminal restoration.

Other Clinical Indications
Other Clinical Indications, encompassing pediatric urology, neurogenic bladder dysfunction, urinary incontinence diagnostics, and post-traumatic reconstructive interventions, accounted for USD 0.24 billion in 2026 and is projected to reach USD 0.34 billion by 2032, advancing at a CAGR of 5.92%. Historical revenues were USD 0.21 billion in 2023, USD 0.21 billion in 2024, and USD 0.22 billion in 2025. Pediatric urology requires miniaturized instrumentation, such as low-caliber cystoscopes, infant resectoscopes, and delicate ureteroscopes designed for pediatric anatomical dimensions. These low-volume, precision-engineered devices are rarely viable in single-use formats due to manufacturing costs, making reusable hardware the primary option for congenital anomaly corrections and pediatric stone disease.

By End User

Hospitals and Integrated Health Systems
Hospitals and Integrated Health Systems constitute the largest purchasing segment, generating USD 3.15 billion in 2026 and projected to expand to USD 4.90 billion by 2032, tracking a compound annual growth rate of 7.66%. The historical market stood at USD 2.65 billion in 2023, USD 2.79 billion in 2024, and USD 2.97 billion in 2025. Hospitals manage high-acuity interventions, complicated surgical oncology, extensive urologic trauma, and inpatient nephrolithiasis. These institutions maintain centralized sterile processing departments capable of managing decontamination, ultrasonic cleaning, and sterilization protocols across hundreds of surgical instruments daily. Hospital purchasing is characterized by multi-facility master service agreements, where integrated delivery networks standardize their urological hardware to achieve volume pricing discounts, streamline biomedical engineering training, and ensure cross-facility equipment compatibility.

Ambulatory Surgery Centers
Ambulatory Surgery Centers represent the fastest-growing end-user classification, valued at USD 1.28 billion in 2026 and projected to achieve USD 2.30 billion by 2032, expanding at a CAGR of 10.35%. Historical performance showed USD 0.95 billion in 2023, USD 1.04 billion in 2024, and USD 1.15 billion in 2025. Payer-driven shifts in surgical site-of-service, combined with surgeon co-ownership models, have driven the migration of elective stone surgery, BPH debulking, and diagnostic cystoscopy into the outpatient setting. ASCs emphasize procedural efficiency, rapid room turnover, and control over supply costs. While single-use scopes appeal to centers with limited sterile processing capacity, high-volume urology ASCs realize significant financial savings by deploying reusable digital scopes managed through rapid automated endoscope reprocessors. This model delivers a lower cost per case over multi-year asset cycles compared to recurring single-use procurement.

Urology Specialty Clinics and Outpatient Practices
Urology Specialty Clinics and Outpatient Practices accounted for USD 0.69 billion in 2026 and are projected to reach USD 1.05 billion by 2032, progressing at a CAGR of 7.42%. Historical values were USD 0.55 billion in 2023, USD 0.59 billion in 2024, and USD 0.63 billion in 2025. These clinical practices represent the front line of diagnostic urology, conducting high volumes of diagnostic flexible cystoscopies, stent removals, intravesical therapy instillations, and urodynamic assessments. Outpatient clinics prioritize compact digital visualization hardware and dedicated, in-office automated endoscope reprocessors that fit into smaller footprints while meeting regulatory standards. These practices amortize scope costs across dozens of routine diagnostic procedures weekly, maintaining reliance on durable, reusable flexible endoscopes.

By Technology Type

Digital Video Endoscopy
Digital Video Endoscopy represents the largest and most dynamic technology segment, generating USD 2.72 billion in 2026 and projected to reach USD 4.76 billion by 2032, demonstrating a CAGR of 9.87%. Historical values reached USD 2.15 billion in 2023, USD 2.31 billion in 2024, and USD 2.50 billion in 2025. Digital endoscopy integrates complementary metal-oxide-semiconductor sensors at the distal tip of flexible cystoscopes, ureteroscopes, and nephroscopes. This eliminates analog glass fiber bundles and delivers native high-definition and 4K digital video directly to surgical displays. Digital architectures incorporate advanced image processing algorithms, including dynamic range correction, red-color enhancement, and narrow-band imaging. These optical capabilities enhance the visualization of subtle mucosal abnormalities and micro-vasculature, assisting in the detection and margins-assessment of urothelial tumors.

Rigid Optical Rod-Lens Systems
Rigid Optical Rod-Lens Systems accounted for USD 1.48 billion in 2026 and are forecasted to achieve USD 2.18 billion by 2032, reflecting a CAGR of 6.64%. The historical baseline stood at USD 1.15 billion in 2023, USD 1.25 billion in 2024, and USD 1.37 billion in 2025. Classical rod-lens systems utilize precisely ground glass cylinders engineered within a stainless-steel sheath to optimize light transmission and optical resolution. These systems are deployed in rigid cystoscopes, semi-rigid ureteroscopes, operative resectoscopes, and rigid nephroscopes. Surgeons rely on rod-lens platforms for their optical clarity, durability, and resistance to image degradation. Furthermore, rigid metal sheaths provide high mechanical stability and fluid channel volume, enabling rapid continuous irrigation during procedures complicated by active hemorrhage.

Fiber-Optic Endoscopy
Fiber-Optic Endoscopy accounted for USD 0.92 billion in 2026 and is projected to reach USD 1.31 billion by 2032, advancing at a CAGR of 6.07%. Historical values were USD 0.85 billion in 2023, USD 0.86 billion in 2024, and USD 0.88 billion in 2025. Fiber-optic systems transmit illumination and images through coherent bundles of optical glass fibers. While this technology is steadily yielding share to chip-on-the-tip digital architectures, fiber-optic instruments maintain a presence in cost-sensitive community hospitals, ambulatory clinics, and specialized clinical scenarios requiring ultra-thin outer sheath diameters. However, the operational reality of broken optical fibers, which create dark pixels and degrade visual fields over time, continues to drive health systems toward modern digital replacements during routine capital refresh cycles.

By Reprocessing Modality

Automated Endoscope Reprocessors
The Automated Endoscope Reprocessors modality segment represents the primary reprocessing category, generating USD 2.82 billion in 2026 and projected to expand to USD 4.70 billion by 2032, tracking a CAGR of 8.86%. Historical performance reached USD 2.30 billion in 2023, USD 2.45 billion in 2024, and USD 2.63 billion in 2025. Regulatory requirements governing endoscope reprocessing have accelerated the migration away from manual high-level chemical disinfection. Modern automated reprocessors provide cycle validation, automated leak testing, and standardized biocidal chemical exposure. Reusable flexible cystoscopes and ureteroscopes are engineered to withstand the chemical exposure and pressure dynamics of automated reprocessor cycles. RFID-enabled connectivity links individual scope serial numbers with unique reprocessing logs, supporting hospital compliance documentation and infection prevention reporting.

Steam Autoclave Sterilization
Steam Autoclave Sterilization accounted for USD 1.33 billion in 2026 and is projected to achieve USD 2.04 billion by 2032, growing at a CAGR of 7.43%. Historical revenues were USD 1.05 billion in 2023, USD 1.13 billion in 2024, and USD 1.23 billion in 2025. Saturated steam under high pressure remains the benchmark for terminal sterilization across healthcare facilities. This modality applies to rigid stainless-steel instrumentation, including resectoscope sheaths, rigid cystoscopes, trocars, dilators, and autoclavable camera heads. Manufacturers continue to utilize heat-resistant optical cements, laser welding, and aerospace-grade stainless alloys, ensuring instruments withstand repeated 134-degree Celsius autoclave cycles without seal degradation or optical misalignment.

Low-Temperature Sterilization
Low-Temperature Sterilization accounted for USD 0.97 billion in 2026 and is projected to expand to USD 1.51 billion by 2032, registering a CAGR of 7.71%. The historical baseline stood at USD 0.80 billion in 2023, USD 0.84 billion in 2024, and USD 0.89 billion in 2025. This category incorporates vaporized hydrogen peroxide, gas plasma, and low-temperature ethylene oxide systems. These platforms address the reprocessing requirements of flexible digital endoscopes, camera heads, and light cables that incorporate heat-sensitive electronic sensors, polymers, and optical adhesives. Healthcare institutions deploy low-temperature sterilization to achieve terminal sterility while protecting capital-intensive digital assets from the thermal stress of steam autoclaves.

Regional Insights: Where the Market is Growing Fastest

The U.S. Reusable Urology Devices Market is geographically segmented into the South, Midwest, West, and Northeast. Demand patterns vary based on regional stone disease prevalence, population age demographics, healthcare infrastructure density, ambulatory surgery center expansion, and health system capital purchasing networks.

South

The Southern region represents the largest geographical market for reusable urology hardware, accounting for USD 2.00 billion in 2026 and projected to reach USD 3.30 billion by 2032, expanding at a CAGR of 8.74%. The market historically generated USD 1.62 billion in 2023, USD 1.73 billion in 2024, and USD 1.86 billion in 2025. The region’s commercial leadership is driven by the convergence of a large and expanding population base, significant Medicare enrollments, and an elevated incidence of urolithiasis linked to the geographic “Stone Belt.” Warm climatic conditions, combined with dietary and metabolic factors, drive stone formation rates that exceed the national baseline. This high clinical volume creates continuous demand for flexible ureteroscopes, laser lithotripsy platforms, and percutaneous nephroscopes across major hospital systems and ambulatory networks.

Texas is the largest state market within the South, generating USD 0.52 billion in 2026 and projected to reach USD 0.88 billion by 2032, at a CAGR of 9.07%. Historical values stood at USD 0.42 billion in 2023, USD 0.45 billion in 2024, and USD 0.48 billion in 2025. Texas possesses major healthcare networks in Houston, Dallas-Fort Worth, San Antonio, and Austin, alongside a large network of independent ambulatory surgery centers. High stone procedure volumes and investment in digital surgical suites drive fleet acquisitions of digital flexible ureteroscopes, high-frequency thulium lasers, and automated endoscope reprocessors.

Florida constitutes the second-largest Southern market, valued at USD 0.47 billion in 2026 and projected to expand to USD 0.77 billion by 2032, advancing at a CAGR of 8.64%. The historical market expanded from USD 0.38 billion in 2023 to USD 0.41 billion in 2024 and USD 0.44 billion in 2025. The state’s demographic profile, marked by a substantial concentration of retirees aged 65 and older, generates high procedural demand for BPH interventions, diagnostic hematuria workups, and bladder cancer surveillance. Regional health systems, including major networks across Orlando, Tampa, and Miami, invest in high-definition digital cystoscope fleets and bipolar resectoscopes to support continuous diagnostic and therapeutic case volumes.

North Carolina accounted for USD 0.20 billion in 2026 and is projected to reach USD 0.33 billion by 2032, exhibiting a CAGR of 8.81%. Historical figures reached USD 0.16 billion in 2023, USD 0.17 billion in 2024, and USD 0.18 billion in 2025. The state benefits from high-density academic and clinical ecosystems in the Research Triangle and Charlotte, which serve as early adopters of advanced digital visualization, thulium fiber lasers, and robotic-assisted urological suites.

Georgia accounted for USD 0.19 billion in 2026 and is projected to reach USD 0.31 billion by 2032, registering a CAGR of 8.65%. Historical totals stood at USD 0.15 billion in 2023, USD 0.16 billion in 2024, and USD 0.17 billion in 2025. Driven by expanding urban healthcare infrastructure in Atlanta and regional health networks serving non-metropolitan populations with high stone prevalence, Georgia healthcare institutions maintain active capital procurement pipelines for durable endourology devices.

Virginia and West Virginia represent distinct healthcare markets within the broader Southern landscape. Virginia generated USD 0.16 billion in 2026 and is forecasted to reach USD 0.26 billion by 2032 at a CAGR of 8.44%, up from USD 0.13 billion in 2023, USD 0.14 billion in 2024, and USD 0.15 billion in 2025. The state’s market is supported by academic medical centers and integrated health networks in the Richmond, Charlottesville, and Northern Virginia corridors. West Virginia generated USD 0.05 billion in 2026 and is projected to reach USD 0.08 billion by 2032 at a CAGR of 7.95%, building upon USD 0.04 billion in 2023, USD 0.04 billion in 2024, and USD 0.05 billion in 2025. Despite its smaller population, West Virginia exhibits high per-capita rates of metabolic syndrome and nephrolithiasis, driving high utilization rates for reusable rigid and flexible stone management equipment relative to its underlying demographic base.

Other Southern states, including Tennessee, Alabama, Louisiana, South Carolina, Kentucky, Mississippi, Arkansas, and Oklahoma, collectively generated USD 0.41 billion in 2026 and are projected to reach USD 0.67 billion by 2032, advancing at an aggregate CAGR of 8.48%. These states historically accounted for USD 0.34 billion in 2023, USD 0.36 billion in 2024, and USD 0.39 billion in 2025. Demand across these states is characterized by regional referral systems managing high rates of acute urolithiasis and chronic urinary retention, requiring durable surgical instruments that deliver long service lifecycles across community hospital networks.

Midwest

The Midwestern region represents a stable, procedurally active market, valued at USD 1.28 billion in 2026 and projected to expand to USD 1.98 billion by 2032, recording a compound annual growth rate of 7.62%. Historical values reached USD 1.05 billion in 2023, USD 1.12 billion in 2024, and USD 1.20 billion in 2025. The Midwest is characterized by established integrated delivery networks, high procedural volumes for BPH and urologic malignancies, and medical device manufacturing and academic clinical trial infrastructure.

Ohio is the largest state market in the Midwest, accounting for USD 0.29 billion in 2026 and projected to reach USD 0.45 billion by 2032, at a CAGR of 7.55%. Historical figures stood at USD 0.24 billion in 2023, USD 0.25 billion in 2024, and USD 0.27 billion in 2025. Major healthcare networks across Cleveland, Columbus, and Cincinnati manage high surgical volumes, driving institutional procurement of digital visualization suites, 4K camera systems, and enterprise automated endoscope reprocessing infrastructure.

Illinois represents the second-largest Midwestern market, generating USD 0.27 billion in 2026 and projected to achieve USD 0.42 billion by 2032, demonstrating a CAGR of 7.76%. Historical performance showed USD 0.22 billion in 2023, USD 0.23 billion in 2024, and USD 0.25 billion in 2025. Capital procurement is concentrated within the Chicago metropolitan area, where academic medical centers and specialized urology groups invest in laser lithotripsy systems, rigid resectoscopes, and digital flexible scopes.

Michigan accounted for USD 0.22 billion in 2026 and is forecasted to reach USD 0.34 billion by 2032, registering a CAGR of 7.50%. Historical performance stood at USD 0.18 billion in 2023, USD 0.19 billion in 2024, and USD 0.21 billion in 2025. Large health networks in Detroit, Ann Arbor, and Grand Rapids emphasize standardized equipment across acute and ambulatory surgical suites, utilizing long-term capital service contracts to ensure high instrument uptime.

Indiana generated USD 0.18 billion in 2026 and is projected to expand to USD 0.28 billion by 2032, at a CAGR of 7.52%. Historical revenues reached USD 0.15 billion in 2023, USD 0.16 billion in 2024, and USD 0.17 billion in 2025. The state’s integrated health systems prioritize cost of ownership models, deploying durable reusable endoscopes and standardizing sterile processing protocols to maximize throughput in high-volume stone and prostate clinics.

Wisconsin and Minnesota represent technology-forward markets characterized by centralized health systems and integrated clinical research centers. Wisconsin generated USD 0.15 billion in 2026 and is projected to reach USD 0.23 billion by 2032 at a CAGR of 7.54%, building on historical levels of USD 0.12 billion in 2023, USD 0.13 billion in 2024, and USD 0.14 billion in 2025. Minnesota generated USD 0.13 billion in 2026 and is projected to reach USD 0.21 billion by 2032 at a CAGR of 7.87%, following USD 0.11 billion in 2023, USD 0.11 billion in 2024, and USD 0.12 billion in 2025. Academic medical centers and health systems across Minneapolis-St. Paul, Rochester, Milwaukee, and Madison serve as early evaluators of miniaturized endoscopes, digital laser integration, and automated cycle-logging reprocessing platforms.

The remaining Midwestern states—including Missouri, Iowa, Kansas, Nebraska, North Dakota, and South Dakota—collectively generated USD 0.24 billion in 2026 and are forecasted to attain USD 0.36 billion by 2032, expanding at an aggregate CAGR of 7.42%. These markets historically accounted for USD 0.20 billion in 2023, USD 0.21 billion in 2024, and USD 0.22 billion in 2025. Healthcare providers across these states balance rural access networks with tertiary surgical centers, maintaining reliance on durable, high-longevity reusable surgical instruments.

West

The Western region represents the fastest-growing market in the United States, generating USD 1.15 billion in 2026 and projected to expand to USD 1.91 billion by 2032, achieving a compound annual growth rate of 8.88%. Historical values reached USD 0.93 billion in 2023, USD 0.99 billion in 2024, and USD 1.07 billion in 2025. Growth in the West is driven by population growth across Mountain and Southwestern states, high rates of ambulatory surgery center expansion, and rapid adoption of digital surgical technologies.

California leads the West in scale, generating USD 0.59 billion in 2026 and projected to expand to USD 0.98 billion by 2032, advancing at an 8.78% CAGR. The state historically generated USD 0.48 billion in 2023, USD 0.51 billion in 2024, and USD 0.55 billion in 2025. California’s large population, extensive network of academic medical centers, and high density of ambulatory surgery centers drive continuous demand across all reusable product segments. Large integrated delivery networks in Los Angeles, the San Francisco Bay Area, and San Diego emphasize clinical efficiency, digital visualization, and sustainable procurement programs that prioritize durable, sterilizable endoscopes over disposable options.

Washington generated USD 0.17 billion in 2026 and is projected to reach USD 0.29 billion by 2032, growing at a CAGR of 9.06%. Historical revenue reached USD 0.14 billion in 2023, USD 0.15 billion in 2024, and USD 0.16 billion in 2025. Integrated health networks and academic hospitals in Seattle and Spokane drive early clinical evaluation and adoption of 4K digital endoscopy towers, automated scope tracking, and thulium fiber laser systems.

Arizona represents an expanding market, valued at USD 0.15 billion in 2026 and projected to reach USD 0.26 billion by 2032, at a CAGR of 9.27%. Historical performance was USD 0.12 billion in 2023, USD 0.13 billion in 2024, and USD 0.14 billion in 2025. Population growth driven by an influx of retirees has increased the local clinical burden of BPH, urolithiasis, and bladder cancer, requiring healthcare networks across Phoenix and Tucson to expand capital urology equipment capacity across outpatient and surgical facilities.

Colorado generated USD 0.11 billion in 2026 and is projected to achieve USD 0.19 billion by 2032, registering a CAGR of 9.17%. Historical figures reached USD 0.09 billion in 2023, USD 0.10 billion in 2024, and USD 0.11 billion in 2025. Hospital networks across the Denver and Colorado Springs corridors continue to invest in ambulatory surgery centers, driving procurement of durable digital flexible scopes and compact automated endoscope reprocessors.

Oregon and Utah represent growing markets driven by organized health systems and population growth. Oregon generated USD 0.08 billion in 2026 and is projected to reach USD 0.13 billion by 2032 at a CAGR of 8.52%, building upon USD 0.06 billion in 2023, USD 0.07 billion in 2024, and USD 0.07 billion in 2025. Utah generated USD 0.07 billion in 2026 and is projected to attain USD 0.12 billion by 2032, tracking a CAGR of 9.42%, up from USD 0.05 billion in 2023, USD 0.06 billion in 2024, and USD 0.06 billion in 2025. Regional integrated health systems in Salt Lake City and Portland focus on procedural efficiency, fleet durability, and centralized sterile processing management.

Other Western states, including Nevada, New Mexico, Idaho, Montana, Wyoming, Alaska, and Hawaii, collectively accounted for USD 0.14 billion in 2026 and are projected to reach USD 0.23 billion by 2032, expanding at a CAGR of 8.51%. Historical figures were USD 0.11 billion in 2023, USD 0.12 billion in 2024, and USD 0.13 billion in 2025. Procurement across these states is shaped by wide geographic distribution, where community hospitals rely on durable reusable instruments supported by regional preventative maintenance agreements.

Northeast

The Northeastern region accounted for USD 0.69 billion in 2026 and is projected to reach USD 1.06 billion by 2032, expanding at a compound annual growth rate of 7.15%. Historical revenues stood at USD 0.55 billion in 2023, USD 0.58 billion in 2024, and USD 0.62 billion in 2025. The Northeast is characterized by a dense concentration of academic medical centers, tertiary cancer institutes, and teaching hospitals. While population growth is lower relative to the Sunbelt, the Northeast maintains high per-procedure value due to its focus on complex oncologic resections, clinical trial participation, and rapid adoption of capital equipment upgrades.

New York is the largest state market in the Northeast, generating USD 0.25 billion in 2026 and projected to achieve USD 0.38 billion by 2032, at a CAGR of 7.18%. Historical performance showed USD 0.20 billion in 2023, USD 0.21 billion in 2024, and USD 0.23 billion in 2025. Health systems across New York City, Long Island, and upstate networks manage high patient acuity and high procedural volumes for bladder and prostate malignancies. These institutions invest in 4K digital visualization towers, narrow-band imaging systems, and automated decontamination platforms to maintain compliance with state and federal infection prevention standards.

Pennsylvania represents the second-largest Northeastern market, valued at USD 0.17 billion in 2026 and forecasted to reach USD 0.26 billion by 2032, tracking a CAGR of 7.02%. Historical revenue reached USD 0.13 billion in 2023, USD 0.14 billion in 2024, and USD 0.15 billion in 2025. Large academic health systems in Philadelphia and Pittsburgh maintain standardized, centralized surgical fleets, driving long-term service agreements and planned capital upgrade cycles for bipolar resectoscopes, thulium fiber lasers, and digital flexible scopes.

Massachusetts accounted for USD 0.11 billion in 2026 and is projected to achieve USD 0.18 billion by 2032, exhibiting a CAGR of 7.42%. Historical values stood at USD 0.09 billion in 2023, USD 0.10 billion in 2024, and USD 0.10 billion in 2025. Anchored by the Boston healthcare and life sciences ecosystem, Massachusetts teaching hospitals serve as reference sites for advanced optical technologies, AI-guided mucosal imaging systems, and specialized pediatric endoscopes.

New Jersey generated USD 0.09 billion in 2026 and is projected to reach USD 0.14 billion by 2032, expanding at a CAGR of 7.08%. Historical revenues were USD 0.07 billion in 2023, USD 0.08 billion in 2024, and USD 0.08 billion in 2025. Integrated health networks across the state emphasize ambulatory surgery center expansion and outpatient diagnostic urology suite modernization.

The remaining Northeastern states—Connecticut, Rhode Island, Maine, New Hampshire, and Vermont—collectively generated USD 0.07 billion in 2026 and are projected to attain USD 0.10 billion by 2032, registering an aggregate CAGR of 6.84%. Historical figures were USD 0.06 billion in 2023, USD 0.06 billion in 2024, and USD 0.06 billion in 2025. These states maintain capital equipment pipelines managed through regional delivery networks, deploying durable reusable instrumentation across both urban academic hospitals and rural healthcare facilities.

Key Market Players

The U.S. Reusable Urology Devices competitive landscape is characterized by established capital equipment manufacturers operating alongside specialized instrument makers, energy console developers, and infection control providers.

Olympus Corporation
KARL STORZ SE & Co. KG
Stryker Corporation
Richard Wolf GmbH
Boston Scientific Corporation
PENTAX Medical (HOYA Group)
Cook Medical
Medtronic plc
Coloplast Corp
Teleflex Incorporated
Laborie Medical Technologies
Lumenis Be Ltd.
Dornier MedTech
Rocamed
Schoelly Fiberoptic GmbH

Olympus Corporation occupies a leading position within the U.S. reusable urology market, underpinned by its installed base of digital flexible cystoscopes, ureteroscopes, and bipolar resectoscopes. The company leverages its proprietary narrow-band imaging technology, which enhances mucosal visualization for bladder cancer surveillance. Olympus reinforces its hardware portfolio with enterprise-level service maintenance agreements, fleet management programs, and automated endoscope reprocessing platforms, securing long-term master contracts with major integrated delivery networks across the country.

KARL STORZ SE & Co. KG is a global leader in optical engineering, recognized for its HOPKINS rod-lens system utilized in rigid cystoscopes, nephroscopes, and resectoscopes. The company’s IMAGE1 S modular visualization platform allows hospital operating rooms to unify endoscopic visualization across urology, gynecology, and general surgery. KARL STORZ has advanced digital flexible ureteroscopy and cystoscopy through the incorporation of distal CMOS sensors and blue-light fluorescence visualization, while expanding its service and repair infrastructure across North America.

Stryker Corporation competes across surgical visualization and endourology, integrating urological instrumentation into its 1688 and 1788 4K surgical imaging platforms. Stryker’s commercial strategy emphasizes cross-specialty hospital procurement bundling, allowing healthcare systems to standardize camera control units, light sources, and documentation consoles across surgical departments. Its urology portfolio includes durable rigid endoscopes, electrosurgical resectoscopes, and a range of reusable laparoscopic instruments.

Richard Wolf GmbH specializes in minimally invasive surgical instrumentation, maintaining a strong market position in endourology, stone management, and extracorporeal shock wave lithotripsy. The company is recognized for its development of miniaturized endoscopes, including the Sensor Ureterorenoscope and specialized systems for mini-PCNL. Richard Wolf emphasizes instrument durability, fluid dynamics engineering, and ergonomics, supporting specialized academic stone centers and high-volume surgical hospitals.

Boston Scientific Corporation, while maintaining an active position in single-use endoscopes, remains a significant player in the reusable urology space through its console-based holmium and thulium laser lithotripsy systems, intracorporeal lithotripters, and capital energy consoles. The company supplies reusable nitinol stone retrieval baskets, access sheaths, dilation balloons, and continuous-flow accessories that integrate with reusable endoscopes across hospital and ambulatory surgery center operating rooms.

PENTAX Medical, an operating division of the HOYA Group, leverages optical sensor and processing engineering to supply digital flexible cystoscopes and diagnostic video systems. The company focuses on distal chip-on-the-tip image resolution, ergonomic handle architecture, and durable channel materials capable of withstanding aggressive automated reprocessing cycles. PENTAX Medical addresses high-volume outpatient clinics and hospital diagnostic urology suites.

Cook Medical maintains an established footprint across the urology surgical landscape, providing durable instrumentation, specialized dilators, metallic urethral sounds, percutaneous access sheaths, and stone extraction accessories. Cook Medical’s instruments emphasize metallurgical engineering, high tactile response, and compatibility with standard steam sterilization, making them basic components of operating room instrument sets nationwide.

Medtronic plc participates in the reusable urology market through surgical instrumentation, electrosurgical generators, and laparoscopic visualization platforms deployed during urologic oncology and reconstructive procedures. Medtronic’s enterprise relationships with hospital group purchasing organizations and integrated health networks enable broad distribution of its capital consoles and specialized surgical instruments across acute-care hospital facilities.

Coloplast Corp provides interventional urology hardware, including specialized access sheaths, fluid irrigation monitoring systems, stone extraction instruments, and reconstructive surgical devices. The company’s products emphasize procedural workflow, patient safety, and compatibility with durable endoscopic visualization systems during complex stone and prosthetic surgeries.

Teleflex Incorporated supplies diagnostic and therapeutic urology instrumentation, specializing in urethral access, rigid instrumentation, and surgical accessories. The company’s portfolio includes reusable components that interface with capital endoscopes, delivering performance during reconstructive and stone-clearing procedures in acute hospital environments.

Laborie Medical Technologies specializes in diagnostic and therapeutic urology hardware, maintaining an established position in urodynamic testing equipment, pelvic health diagnostic consoles, and specialized cystoscopic delivery systems. Laborie’s capital systems are widely deployed across hospital outpatient clinics and independent urology practices to evaluate lower urinary tract symptoms, urinary incontinence, and neurogenic bladder dysfunction.

Lumenis Be Ltd. is an established developer of energy-based surgical systems, known for its high-power holmium:YAG laser platforms, including the Pulse series. These capital consoles support both lithotripsy dusting and holmium laser enucleation of the prostate. Lumenis continues to innovate in pulse-modulation technologies that minimize stone retropulsion while preserving operative vision through reusable endoscope channels.

Dornier MedTech specializes in kidney stone management technologies, manufacturing extracorporeal shock wave lithotripsy systems, high-frequency surgical laser consoles, and specialized urological surgical tables. Dornier’s platforms are deployed across outpatient lithotripsy centers, mobile medical service networks, and hospital surgical departments, offering integrated imaging and stone localization software.

Rocamed is a specialized manufacturer of endourological instruments, providing flexible and semi-rigid ureteroscopy accessories, stone extraction devices, laser delivery fibers, and fluid irrigation control platforms. The company’s products emphasize instrument durability, hydrodynamic efficiency, and compatibility with leading capital visualization and laser consoles.

Schoelly Fiberoptic GmbH is an engineering and original equipment manufacturing provider of optical visualization systems, micro-endoscopes, camera control units, and light sources. In addition to marketing proprietary visual inspection hardware, Schoelly serves as a design and manufacturing partner for global medical device brands, engineering miniaturized 4K distal chip-on-the-tip camera modules and autoclavable optical rod-lens systems utilized in modern urology suites.

Recent Developments

The U.S. reusable urology device industry has experienced key regulatory, technological, and corporate developments over recent cycles, altering capital equipment procurement, device engineering, and sterile processing protocols.

In 2024, the Food and Drug Administration, in collaboration with the American Urological Association, updated its safety communications and guidance documents regarding the reprocessing of flexible urological endoscopes. Prompted by historic investigations into cross-contamination risks associated with endoscope lumina, regulatory agencies emphasized the necessity of strict, validated cleaning protocols, automated leak testing, and the transition toward automated endoscope reprocessors over manual disinfection. Manufacturers responded by redesigning flexible cystoscopes and ureteroscopes to feature seamless, crevice-free internal channels, non-porous polymer outer sheaths, and laser-welded distal caps capable of withstanding harsher, low-temperature chemical biocides without optical degradation. This regulatory guidance formalized health-system investments in automated cycle-logging reprocessing platforms, integrating infection control tracking into hospital information technology networks.

The commercialization of high-frequency Thulium Fiber Laser systems expanded significantly through 2025. Major players, including Olympus, Boston Scientific, and Lumenis, expanded their TFL capital platforms. Clinical studies confirmed that the 1,940-nanometer thulium fiber laser wavelength, which matches the water absorption peak in urinary calculi, achieves efficient stone dusting while producing less retropulsion than conventional holmium:YAG systems. Because thulium platforms deploy thinner optical fibers (ranging from 150 to 200 microns in core diameter), they preserve the active deflection mechanics of flexible digital ureteroscopes and allow for higher continuous irrigation flow rates. This technical advance has reduced intraoperative scope channel damage, lowered average repair expenditures, and improved total cost of ownership metrics for high-volume stone centers utilizing reusable scopes.

Digital integration and visualization platform modernization advanced in 2025 and 2026. Industry leaders, including KARL STORZ and Olympus, introduced modular 4K and multi-spectral video processing platforms engineered for urologic surgery. These systems integrate native narrow-band imaging, blue-light fluorescence, and dynamic contrast enhancement software, providing structural visualization of flat carcinomas in situ and micro-vascular mucosal abnormalities during surveillance cystoscopy. Furthermore, manufacturers integrated wireless video transmission, direct electronic medical record image archiving, and artificial intelligence-driven video indexing. These developments allow urologists to capture, annotate, and store operative findings within patient electronic records without external capture cards or manual data transfer.

Corporate transaction activity and procurement contracting models have shifted toward comprehensive fleet management and service risk-sharing. Driven by capital budget constraints in community hospitals and margin considerations in ambulatory surgery centers, medical device companies expanded uptime-guaranteed service agreements. Under these contractual frameworks, the vendor guarantees immediate, overnight scope replacement for damaged units, provides scheduled preventative maintenance, and bundles periodic digital visualization upgrades into a predictable multi-year operational expenditure structure. This procurement approach mitigates the historical financial uncertainty of unexpected repair costs, allowing reusable device platforms to maintain cost competitiveness against single-use, disposable alternatives in high-volume surgical institutions.

Conclusion

The U.S. Reusable Urology Devices Market is positioned to expand from USD 5.12 billion in 2026 to approximately USD 8.25 billion by 2032, driven by a compound annual growth rate of 8.27% across the forecast period. Historical market performance, expanding from USD 4.15 billion in 2023 to USD 4.42 billion in 2024 and USD 4.75 billion in 2025, reflects normalized surgical case volumes, the replacement of aging capital visualization systems, and continuous procedure growth across ambulatory surgical networks.

The structural drivers of the market remain resilient. The expanding clinical burden of urolithiasis, accelerated by demographic trends, dietary patterns, metabolic disease, and regional climatic factors, provides an ongoing procedural baseline. The aging U.S. population ensures growing surgical demand for BPH interventions, including bipolar resection, holmium enucleation, and thulium laser vaporization. Furthermore, the non-discretionary nature of lifelong endoscopic surveillance for urothelial and bladder carcinomas ensures steady, predictable procedural demand across thousands of hospital outpatient departments and specialty clinics nationwide.

While single-use disposable endoscopes have established a presence in low-volume community hospitals and emergency departments managing off-hours interventions, reusable urology devices remain the primary standard for high-throughput ambulatory surgery centers, academic medical centers, and high-volume health systems. When managed through automated, cycle-validated reprocessing protocols, the amortized cost per procedure of a durable digital endoscope delivers superior economic performance over multi-year asset lifecycles, while avoiding the biomedical waste generation associated with disposable instruments.

The strongest revenue growth opportunities through 2032 will center on digital chip-on-the-tip flexible ureteroscopes, 4K modular video processing platforms, high-frequency thulium fiber laser systems, and automated, RFID-enabled endoscope reprocessing suites. Urolithiasis will remain the largest disease indication, driving capital hardware procurement across hospitals and ambulatory networks. BPH and urothelial malignancies will provide stable demand for durable resectoscopes and high-definition surveillance cystoscopes.

Geographically, the South will maintain its market leadership, driven by population growth, Medicare enrollment density, and the geographic concentration of stone disease within the “Stone Belt,” anchored by Texas and Florida. The West will record the fastest rate of growth, powered by regional population expansion, extensive ambulatory surgery center penetration, and rapid adoption of digital surgical platforms in California, Washington, and Arizona. The Midwest will continue to offer a stable capital replacement environment across its integrated delivery networks in Ohio, Illinois, and Michigan, while the Northeast will drive the early adoption of advanced optical imaging and academic clinical innovations across New York, Pennsylvania, and Massachusetts.

For medical device manufacturers, institutional healthcare buyers, and clinical leaders, competitive differentiation in the reusable urology hardware market will be governed by total cost of ownership, instrument durability, optical performance, and seamless reprocessing integration. Platforms that combine advanced diagnostic visualization with resilient structural engineering, low-temperature sterilization compatibility, and comprehensive uptime-guaranteed service models will lead hospital capital procurement decisions and maintain long-term market leadership through 2032.